Humacyte, Inc. (HUMA)
After hours:
- GuruFocus.com
Humacyte Inc (HUMA) Q1 2024 Earnings: Aligns with Analyst Projections Amid Strategic Advances
Key Financial and Operational Highlights from the First Quarter
- GlobeNewswire
Humacyte First Quarter 2024 Financial Results and Business Update
-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43 million in net proceeds from public offering of common stock- -Conference call and live webcast at 8:00 a.m. ET today- DURHAM, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at com
- GlobeNewswire
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2024, on Friday, May 10, 2024. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte First Quarter 2024 Financial Results and Corporate UpdateDa
